1. Impact of Ki67 and progesterone receptor on PFS with cyclin-dependent kinase 4/6 inhibitors in HER2-negative advanced breast cancer: A real world mono-institutional experience. (October 2020) Authors: Palleschi, M.; Barzotti, E.; Melegari, E.; Manunta, S.; Mannozzi, F.; Vagheggini, A.; Maltoni, R.; Fedeli, A.; Sarti, S.; Cecconetto, L.; Possanzini, P.; Ravaioli, S.; Tumedei, M.M.; Amadori, D.; Bravaccini, S.; Rocca, A. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 1 Page Start: S66 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. New Biomarkers to Predict the Evolution of In Situ Breast Cancers. (26th August 2014) Authors: Bravaccini, S.; Tumedei, M. M.; Scarpi, E.; Zoli, W.; Rengucci, C.; Serra, L.; Curcio, A.; Buggi, F.; Folli, S.; Rocca, A.; Maltoni, R.; Puccetti, M.; Amadori, D.; Silvestrini, R. Other Names: Mehta Kapil Academic Editor. Journal: BioMed research international Issue: Volume 2014(2014) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗